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Introduction
Several strategies to generate tolerogenic dendritic 
cells (DCs) are under evaluation in the attempt to 
modulate the immune response in several diseases. 
Studies,1–4 including those performed in our labo-
ratory5–7 show that administration of oral protein 
leads to the generation of tolerogenic dendritic 
cells (DC) not only in the mucosal, but also in sec-
ondary lymphoid organs such as spleen. We previ-
ously showed that, in the presence of ovalbumin 
(OVA), spleen DCs from tolerant BALB/c mice 
co-cultured with naïve OVA-specific T cells polar-
ize T cells preferentially to TGF-β producing Th3 
cells.5 The DO11.10 mice, which bear 80% of 
transgenic T-cell receptor (TCR)-α and -β chains 
that recognize the OVA peptide OVA323–339 that 
binds to I-Ad MHC class II protein, have been used 
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in studies of oral tolerance to OVA, particularly in 
relation to T-cell proliferation and cytokine secre-
tion.8,9 However, we have previously shown that, 
opposite of BALB/c mice, DO11.10 mice were not 
susceptible to tolerance after OVA ingestion. In 
this transgenic model, the continuous feeding with 
OVA did not modulate the antibody production and 
proliferative response.5,10,11
Another line of research has shown that nitric 
oxide (NO), a free radical produced by hydrolysis 
of L-arginine by the action of induced nitric oxide 
synthase (iNOS), can downregulate the immune 
response mediated by CD4+ T lymphocytes. Nitric 
oxide is involved in several physiological events 
such as vascular relaxation, neurotransmission, 
defense against pathogen, and regulation of in vivo 
adaptive immune response.12–16 However, overpro-
duction of NO by activated phagocytes has been 
implicated in the destruction of healthy tissue in the 
adjacent area of inflammation, thereby contributing 
to the pathogenesis of several diseases.14,17–20
On the other side of the metabolic pathway of 
L-arginine, the enzyme arginase (Arg) converts 
L-arginine into L-ornithine and urea. Mammalian 
cells express the two isoforms of Arg, named Arg I 
and Arg II.21 Arg I controls the availability of argi-
nine in activated macrophages and downregulates 
NO synthesis.22 iNOS and arginase use the same 
substrate and compete in conditions of limited 
availability of L-arginine.21 Although the affinity 
of L-arginine is higher for NOS than for arginase, a 
maximum activity of arginase is 1000-fold higher 
than NOS.23
Although the involvement of iNOS and Arg on 
macrophage response is well-known,12,17,22,24–29 
few studies report the effects of the modulation of 
these enzymes on DC functions, and they only 
address the in vitro effects of such modula-
tion.24,30–33 In this regard, small amount of NO pro-
duction by in vitro-generated bone marrow DCs 
(BMDCs) seems to be able to inhibit T-cell prolif-
eration. Literature shows that CD4+T cells are able 
to proliferate in the presence of DCs expressing 
iNOS or not. The addition of IFN-γ to co-cultures 
potentiated the activity of iNOS and subsequent 
release of NO in the supernatant reduced the prolif-
eration of CD4+ T lymphocytes and induced T-cell 
apoptosis.13 However, conflicting data showed that 
inhibition or absence of iNOS induces tolerance to 
dietary antigen.34
The activity of both iNOS and Arg1 has also 
been correlated with the capacity of DCs to expand 
and differentiate regulatory T cells in the periph-
ery.31,33,35–37 Cytokines secreted by Th1 and Th2 
cells can competitively regulate the activity of 
iNOS and arginase15,24 in macrophages and DCs. 
Th1 immune responses lead to the induction of 
iNOS, resulting in production of NO, whereas Th2 
responses upregulate arginase expression.24,38,39 
Specifically, it was demonstrated that interleukin 
(IL)-4 and IL-10 induce the expression of arginase, 
whereas IFN-γ induces iNOS and inhibits Arg1 on 
macrophages and DC, in a clear Th1 and Th2 oppo-
sition.14,40 Specific inhibitors of NOS (Nω-nitro-L-
arginine methyl ester;L-NAME)41 and arginase 
(Nω-hydroxy-L-arginine; NOHA)42 are currently 
used to investigate NO activity in adjuvant-induced 
arthritis, experimental colitis, and pulmonary alle
rgy.17–20,43,44 The non-selective inhibitor L-NAME 
was able to block activity of constitutive NOS 
(cNOS). On the other hand, NOHA is an interme-
diate in the biosynthesis of NO by NOS and a 
physiological competitive inhibitor of arginase 
activity.23,45
In the present study, we evaluated the effects of 
the treatment with NOHA and L-NAME on pheno-
type and activity of BMDCs. We also analyzed the 
effects of adoptive transfer of modulated BMDCs 
on immune response to OVA of BALB/c and 
DO11.10 mice.
Our hypothesis is that the inhibition of iNOS 
and arginase can drive BMDCs into a tolerogenic 
profile. Our results indicate that modulation of 
BMDCs with arginase and iNOS inhibitors may be 
an important strategy to induce tolerance to anti-
gens involved in the pathogenesis of inflammatory 
diseases.
Material and methods
Mice. Mice carrying the MHC class II restricted 
rearranged T cell receptor transgene, Tg (DO11.10) 
10Dlo, here named DO11.10 mice,46 and wild-type 
BALB/c mice were supplied by CEMIB (Centro 
Multinstitucional de Investigações Biológicas), 
UNICAMP and housed in pathogen-free condi-
tions and fed a diet of autoclaved food and water. 
The study was approved by the institutional 
Committee for Ethics in Animal Experimentation 
(protocol no. 911-1).
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Immunization. Mice were intraperitoneally chal-
lenged with 10 mg of OVA mixed with 1 mg of 
aluminum hydroxide in saline solution. After 14 
days, the mice received a reinforcement dose of 10 
mg of the antigen in saline solution. The mice were 
bled by the retro-orbital plexus after 7 days and 
sera were separated for antibody assays.
Antibody assays. Antibody titers to OVA were 
determined by a standard enzyme linked immuno-
sorbent assay (ELISA) using an automatic reader 
(Multiskan II, MS, Labsystem, Helsinki, Finland) 
as described elsewhere.5 Briefly, each well of a 
microtiter plate (Falcon, Becton-Dickinson, 
Franklin Lakes, NJ, USA) was coated with 1 µg of 
OVA in carbonate/bicarbonate buffer pH 9.5 and 
incubated overnight at 4°C. The wells were washed 
and blocked with 5% skimmed milk in phosphate 
buffered saline (PBS) pH 7.4. After new washing 
cycle, the plates were incubated for 1 h with mouse 
serum samples diluted with 2% skimmed milk in 
PBS pH 7.4 from 1:100 to 1:12,800. The washed 
plates were incubated with a rabbit anti-mouse Ig–
HRPO conjugate (275 ng/mL) in 2% skimmed 
milk in PBS pH 7.4 for 1 h. The reaction was 
revealed by adding freshly prepared substrate 
(0.04% orthophenylenediamine and 0.03% H2O2 
in 50 mM citric acid/di-sodium hydrogen phos-
phate buffer, pH 5.5). The reaction was stopped 
after 30 min and the absorbance was read at 492 
nm. The ELISA scores were computed by running 
sums of the optical densities for the serum dilu-
tions (1:100–1:12,800) for individual mice, and 
were expressed as the mean ± SEM of five mice 
from each group.
BMDCs. BMDCs were generated from bone 
marrow precursors as described elsewhere.47,48 
Briefly, bone marrow cells were flushed from 
femurs and tibia of naïve BALB/c mice. Cells were 
seeded in six-well plates (Corning) at a density of 
2 × 106 cells/well in RPMI 1640 medium (Sigma) 
containing 10% fetal bovine serum (FSB, Cultilab), 
20 µg/mL gentamicin (USB), and 20 ng/mL of 
mouse recombinant granulocyte macrophage col-
ony-stimulating factor (mrGM-CSF) (Biosource) 
and cultured at 37°C. On days 3 and 6, the culture 
medium was replaced. After 8 days of culture, 
BMDCs were harvested and re-cultured in 24-well 
plates at a density of 2.5 × 106 cells per well in the 
presence of either L-NAME at 1 mM or NOHA at 
750 µM. BMDCs cultured in the absence of stimuli 
were used as control. After 48 h of the onset of the 
cultures, 100 mg/mL OVA (Conalbumin, Sigma) 
were added to monolayers that were incubated for 
additional 18 h.
Measurement of nitric oxide. Dosages of NO 
were used as described previously.49–51 Briefly, 50 
µL of the culture supernatants of BMDCs cultured 
in the presence or absence of LPS + TNF-α were 
collected and transferred to a 96-well plate (Nunc, 
Nunclon) in triplicates. Then, 50 µL of Griess rea-
gent were added to supernatants. After stirring, 
spectrophotometric readings were carried out on 
an ELISA reader (Multiskan MS, Labsystems, 
USA) at 540 nm. The concentration of nitrite 
(mM/1 × 106 cells) was calculated based on a 
standard curve of a sodium nitrite solution at 320, 
160, 80, 40, 20, 10, and 5 mM. The results were 
expressed as mean ± SEM.
Measurement of urea. BMDC cultures were 
used for detection of arginase activity according to 
the methodology described elsewhere50,52 with 
some changes. Briefly, after removing the superna-
tant, the cells in monolayers were lysed by adding 
50 µL/well of lysis solution (0.1% Triton X-100, 5 
mg aprotinin and trypsin inhibitor, and 5 mg of 
antipain or PMSF) and the plates were kept under 
mild stirring for 30 min at room temperature. Then, 
50 µL Tris-HCl 50 mM, pH 7.5 containing 10 mM 
MnCl2 was added to each well and the plates were 
incubated at 55°C for 10 min to activate the 
enzyme. Aliquots of 25 µL of activated lysates 
were transferred to Eppendorf tubes and 25 µL of 
0.5 M L-arginine (Sigma, St. Louis, MO, USA), 
pH 9.7 was added. After 60 min incubation at 37°C, 
the L-arginine hydrolysis reaction was stopped by 
adding 400 µL of a mixture of H2SO4, H3PO4, and 
H2O (1:3:7). Then, 25 µL of a solution ISPF 9% in 
absolute ethanol was added to each reaction tube 
and the mixtures were heated for 45 min at 100°C. 
After resting for 10 min at room temperature in the 
dark, absorbance was measured in microplate 
reader (Multiskan MS, Labsystems, USA) at 540 
nm. The quantity of urea in the reaction was deter-
mined by comparison with the absorbance of urea 
standard curve (1.5–1200 mg/mL). For spectro-
photometric measurements of urea standard solu-
tions, aliquots of 100 µL of each of the curve points 
were distributed in the microtiter plate in quadru-
plicate and then each well was filled with 400 µL 
of the mixture of acids and 25 µL of ISPF in 
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absolute ethanol. The results were expressed as 
mean ± SEM. The urea concentration in the sample 
in µg/106 cells/mL.
Flow cytometry analysis. The DC generation 
was accompanied by flow cytometry (FACSAria, 
Becton-Dickinson), using anti-mouse CD11c- allo-
phycocyanin (APC) conjugate (clone HL-3; BD 
PharMingen, San Diego, CA, USA); anti-class II 
MHC-PE conjugate (clone M5/114.15.2, Multinyi 
Biotec); anti-CD80-FITC (clone 14-10A1), anti-
CD86-FITC (clone GL1, BD PharMingen), and 
anti-CD40 FITC (clone 3/23, BD-Pharmingen) as 
described previously.53 The cells were also stained 
with irrelevant isotype controls (BD PharMingen) 
for each cell marker.
Amplification and compensation were deter-
mined by the examination of non-marked cells and 
analyses were carried out using the FCS-Express 
software. Data were represented as percentage of 
positive cells (%) and geometric mean fluores-
cence intensity (MFI).
BMDC transfer. BMDCs generated as described 
above were collected, pelleted at 200 g for 5 min to 
remove stimulus, and cell concentration was 
adjusted to 5 × 106 cells/mL in 0.15M NaCl. 
Aliquots of 100 µL of the cell suspension were 
injected into the retro-orbital venous sinus of each 
mouse of BALB/c or DO11.10 lines.
Antigen-specific proliferation. T-cell prolifera-
tion assays were carried out as described else-
where.10,53 Briefly, spleen cells or mesenteric 
lymph nodes (MLN) (5 × 105 cells/well) were cul-
tured in the presence of the antigen (0.1 mg/mL 
OVA) for 96 h and supernatants were collected for 
cytokine determination. 3-[4,5-dimethyltiazol-
2-yl] diphenyltetrazolium bromide solution (MTT, 
Sigma, St. Louis, MO, USA) was added to the cul-
tures (5 mg/mL; 10 µl/well) and incubated for an 
additional 4 h. After dissolving of formazan crys-
tals, the optical densities were measured at 540 nm. 
TCD4+ cells were enriched from spleens of 8-week-
old naïve BALB/c mice using CD4 microbeads, as 
indicated by manufacturer (Miltenyi Biotec, 
Germany). Purification (higher of 95%) was 
accompanied by flow cytometry with antibodies 
anti-CD3-PE and anti-CD4-FITC (BD PharMingen, 
San Diego, CA, USA).5,10
Co-cultures of DC-Tcells and CD28+, CTLA4+, 
and CD25+Foxp3+ cell staining. DCs and T-cell co-
culture assays were carried out as described else-
where.7 T cells (5 × 105 cells/well) and DCs (2 × 104 
cells/well) were co-cultured in the presence of the 
antigen (1 mg/mL OVA) for 96 h. Co-cultures of 
CD3+CD4+ cells were gated and populations marked 
to determinate the CD28+, CTLA4+, and 
CD25+Foxp3+ cells as described. Briefly, single cell 
suspensions were washed and suspended in staining 
buffer (PBS plus 0.1% bovine serum albumin plus 
0.09% sodium azide [BD Becton Dickinson, San 
Jose, CA, USA]) and stained with surface the mark-
ers anti-CD3-PerCP-Cy5.5, anti-CD4-PECy7, anti-
CD25 FITC, anti-CD28+ PE, and anti-CTLA4+ PE 
and their respective isotype controls for 30 min at 
4°C. The samples that were used to analyze 
CD25+Foxp3+ Tregs were additionally incubated 
with fixation/permeabilization buffers (Mouse 
Foxp3 Buffer Set – BD Pharmingen) for 30 min, 
according to the manufacturer’s instructions, and 
stained with anti-mouse-Foxp3 PE, antibody, and the 
respective isotype control. All FACS reagents were 
purchased from BD Bioscience (San Jose, CA, USA) 
and used following the manufacturer’s recommenda-
tion. Amplification and compensation were deter-
mined by the examination of non-marked cells and 
analyses were carried out using the FCS-Express 
software. Data were represented as percentage of 
positive cells (%) and geometric MFI.
Cytokine measurement. The levels of IL-2, IL-4, 
IL-10, IFN-γ, and TGF-β were measured in co-
culture supernatants using BD–OptEIATM ELISA 
sets, according to the manufacturer’s instructions. 
Absorbances were read at 450 nm, with the wave-
length of 540 nm used for correction.
Statistical analysis. Differences were statisti-
cally analyzed using a one-way ANOVA with a 
Bonferroni post-test. The software Prism (version 
5.0, Graphpad Software, Inc., San Diego, CA, 
USA) was used to prepare graphics and for statisti-
cal analysis. P values <0.05 were considered statis-
tically significant. Data are presented as the mean 
± SEM.
Results
In this work, we aim to evaluate the effects of 
adoptive transfer of BMDCs modulated with iNOS 
and arginase inhibitors upon the development of 
immune response in BALB/c and DO11.10 trans-
genic mice. To our knowledge, this is the first work 
showing the modulatory effects of the inhibition of 
arginase and iNOS in DCs on the immune response 
to an exogenous antigen.
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First of all, we determined the effective minimal 
doses of L-NAME and NOHA used in the treat-
ments of BMDCs and we found that these drugs 
were able to significantly inhibit iNOS and Arg 
activities in doses as low as 1 mM and 750 µM, 
respectively (data not shown). As expected, the 
pretreatment of BMDCs with 1 mM L-NAME led 
to a significant decrease in nitrite production in 
BMDCs stimulated with LPS + TNF-α (Figure 1a). 
With respect to treatment with NOHA, it was 
observed that the dose of 750 µM led to a signifi-
cant inhibition of urea production in BMDCs 
treated and not treated with IL-4 (Figure 1b).
The BMDCs treated with the inhibitory drugs 
L-NAME and NOHA were also evaluated for 
expression of co-stimulatory molecules CD80, 
CD86, and CD40 in the CD11c+ MHCII+ subsets. 
Analysis by flow cytometry showed no change in 
CD40 expression after treatment with L-NAME or 
NOHA, compared to untreated cells (data not 
shown). When CD86 expression was analyzed, we 
noticed significant increase in the expression of 
this molecule in BMDCs treated with either 
L-NAME or NOHA, whereas the expression of 
CD80 was significantly increased only after the 
treatment with NOHA (Figure 2a).
The activity of both iNOS and Arg1 can also 
been correlated with the capacity of DCs to expand 
regulatory T cells in the periphery, as demonstrated 
here. In this regard, we observed that BMDCs 
treated with saline or L-NAME were able to expand 
in vitro the population of CD4+CD25+Foxp3+ cells 
in co-cultures with TCD4+ cells (Figure2b).
Effects of administration of NOHA or L-NAME 
modulated BMDCs on immune response of 
BALB/c mice
To evaluate the effects of modulation of DCs on 
the immune response, BMDCs were treated with 
the iNOS (L-NAME) and arginase (NOHA) 
inhibitors and adoptively transferred to naïve 
BALB/c or DO11.10 (OVA-TCR) mice. NOHA 
or L-NAME-modulated BMDC, as well as non-
modulated BMDC, were adoptively transferred to 
naïve wild-type BALB/c and transgenic DO11.10 
mice. All mice were i.p. immunized with OVA. 
After antigenic challenge, the levels of antibodies 
in serum, antigen specific-proliferative response, 
and cytokine production were evaluated in the 
cultures of spleen and mesenteric lymph nodes 
(MLN).
As depicted in Figure 3a, the adoptive transfer 
of BMDCs modulated with either L-NAME or 
NOHA was able to reduce the levels of OVA-
specific antibody in sera of immunized BALB/c 
mice, and NOHA-modulated BMDCs apparently 
seems to be more effective in this regard.
Our results show that the adoptive transfer of 
BMDCs modulated with either L-NAME or NOHA 
led to the reduction of in vitro antigen specific pro-
liferation of both spleen cells and MLN cells from 
immunized BALB/c mice in comparison to the 
transfer of non-modulated BMDCs. Interestingly, 
an increase in antigen-specific proliferation was 
observed in cultures of the spleen and MLN cells 
of immunized BALB/c mice adoptively transferred 
with non-modulated BMDCs compared with that 
observed in cell cultures of untreated mice (Figure 
3b, c).
The secretion of IFN-γ, IL-4, IL-10, and TGF-β 
was more reduced in cultures of spleen cells 
obtained from BALB/c mice adoptively transferred 
with BMDCs modulated with either L-NAME or 
Figure 1. INOS and arginase activities in BMDCs upon 
treatment with inhibitors of L-arginine metabolism. BMDCs 
were generated in vitro and cultured in the presence of 
either L-NAME (1 mM) or NOHA (750 μM) for 24 h. BMDCs 
cultured in the absence of inhibitors were used as control 
group. (a, b) LPS (1 µg/mL) + mrTNF-α (20 ng/mL) or rmIL-4 
(40 ng/mL) were added to the culture wells, to induce iNOS 
and Arg-1 activities, respectively, and plates were incubated 
for an additional 24 h. In all groups, BMDCs cultured in the 
absence of stimuli were used as controls. Culture supernatants 
were collected to NO detection (a) and cells were lysed to 
evaluated arginase activity by urea assay (b). (*) means P <0.05. 
The non-treated group did not receive any stimuli.
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NOHA in comparison with cultures of cells 
obtained from mice treated with non-modulated 
BMDCs (Figure 3, D-M). However, compared to 
the control group (mice that did not receive 
BMDCs), secretion of IL-4, IL-10, and IFN-γ was 
upregulated in the cultures of spleen cells from 
BALB/c mice transferred with BMDCs modulated 
with the inhibitors or not.
Effects of administration of NOHA or L-NAME 
modulated BMDCs on immune response of 
DO11.10 mice
To evaluate the effects of L-arginine metabolism 
on the immune response of an OVA-TCR-specific 
model, unmodulated BMDCs or BMDCs modu-
lated with L-NAME or NOHA were adoptively 
transferred to naïve DO11.10 transgenic mice. 
Antibody levels, antigen-specific proliferative 
response, and cytokine production were evaluated 
as previously described.
As depicted in Figure 4a, transfer of either non-
modulated BMDCs or BMDCs modulated with 
iNOS or arginase inhibitors equally increase the 
specific humoral immune response of DO11.10 
mice, in comparison to untreated immunized mice 
(dashed line). Antigen-specific proliferation of 
spleen T cells was not affected by adoptive transfer 
of either modulated or non-modulated BMDCs 
(Figure 4b). A slightly increased proliferation of 
antigen-specific cells was observed only in cultures 
of MLN cells from DO11.10 mice adoptively trans-
ferred with NOHA-modulated BMDCs (Figure 4c).
As illustrated in Figure 4, IL-2 was more ele-
vated in supernatants of spleen cells and MLN 
cells from DO11.10 mice treated with either non-
modulated or modulated BMDCs in comparison to 
untreated mice (dashed line), but cells of both 
compartments collected from mice adoptively 
transferred with L-NAME-modulated BMDCs 
was less effective in producing this cytokine 
(Figure 4d, e). IFN-γ levels rise in cultures of MLN 
cells from DO11.10 mice transferred with 
L-NAME-modulated BMDCs in comparison to 
untreated mice, but were lower in supernatants of 
MLN cells from transgenic mice transferred with 
NOHA-modulated BMDCs (Figure 4g). IL-4 lev-
els also rise in the cultures of spleen cells of all 
Figure 2. Effects of L-NAME or NOHA treatment on surface markers expression and frequency of BMDCs and T cells. (a) DCs 
were generated in vitro by culture of bone marrow precursors with GM-CSF for 8 days and cultured with L-NAME (1 mM), NOHA 
(750 μM), or RPMI for 48 h. BMDCs were labeled with anti-CD11c-APC, anti-MHC class II-PE, anti-CD86-FITC, and anti-CD80-
FITC antibodies and analyzed by flow cytometry. Data represents the percentage of positive cells (%) and geometric MFI of cells 
over background staining with an isotype-matched control (hatched line). Data are representative of two separate experiments.  
(b) DCs were generated in vitro by culture of bone marrow precursors with GM-CSF for 8 days and cultured with L-NAME  
(1 mM), NOHA (750 μM), or saline for 48 h and co-cultured with T CD4+ cells obtained from OVA immunized BALB/c mice, as 
described on M. CD25+Foxp3+ markers were stained on TCD4+ population and represented as percentages. CTLA-4 and CD28 
molecule expression on TCD4+ population were expressed on MFI. Data represent the percentage of positive cells (%) and 
geometric MFI over background staining with an isotype-matched control (hatched line). Dashed line represents non-stimulated 
TCD4+ cells. Data are representative of two separate experiments.
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groups in comparison to untreated mice, except in 
cell cultures from mice that received NOHA-
modulated BMDCs (Figure 4h, i). Although statis-
tically non-significant (due to high dispersion), an 
augment of IL-10 was observed in supernatants of 
spleen cell cultures from DO11.10 mice treated 
with BMDCs modulated with L-NAME or NOHA 
(Figure 4j, k). TGF-β was not detected in spleen 
cell cultures and was below the control group in 
cultures of MLN (Figure 4l, m).
Discussion
Mononuclear phagocytic cells such as mac-
rophages and DCs use two types of enzymes to 
metabolize L-arginine: arginase (Arg) and induci-
ble nitric oxide synthase (iNOS). The Arg I and II 
are able to metabolize L-arginine into L-ornithine 
and urea, while the iNOS convert L-arginine to 
L-citrulline and NO.26,54 Although iNOS and Arg 
are well studied in macrophages, there are few 
reports related to the role of these enzymes on DC 
functions.24,30
Although there are some studies on the conse-
quences of inhibition of iNOS and arginase in DCs, 
literature has already shown that the blockage of 
NOS by Manassantin A (MSA), an inhibitor of the 
nuclear transcription factor-kappa B (NF-κB) led 
to a reduction of the expression of MHC I, MHC II, 
CD40, CD80, and CD86 molecules in BMDC, 
even in the presence of LPS.55 As a consequence of 
treatment with MSA, the authors report that the 
maturation of DCs is compromised as well as their 
ability to induce allogeneic T-cell activation. 
Myeloid-derived suppressor cells (MDSC), which 
include immature macrophages, granulocytes, 
Figure 3. Adoptive transfer of BMDCs modulated with L-NAME or NOHA reduces antibody levels and antigen specific proliferation 
of immune cells in BALB/c mice. To perform the adoptive transfer, BALB/c mice (n = 6 per group) were injected by intravenous 
route with 5 × 105 BMDCs cultured in the presence of L-NAME (1 mM) or NOHA (750 μM) for 48 h. A group of mice that received 
BMDCs cultured in the absence of inhibitors was included as control. One day later, mice of all groups were challenged with 10 mg 
OVA + 1 mg Al(OH)3 by intraperitoneal route. At day 14, mice were boosted with 10 μg OVA in saline solution. Seven days after 
the last antigenic dose, mice were killed for evaluations. Sera were separated for measuring anti-OVA antibody levels in ELISA tests, 
and spleens and lymph nodes were removed aseptically for measuring antigen specific proliferation by MTT method. (a) The bars 
represent the mean ± SEM of the sum of absorbance values of individual serum dilutions from 1:100 to 1:12,800 in ELISA assays. (b, 
c) The bars represent the mean of absorbance ± SEM measured in the cultures subtracting naïve basal proliferation of spleen (b) 
and lymph node (c) cells. Cultures were performed in six replicates. Data are representative of two separate experiments. *P <0.05 
compared with control group. Comparisons were carried out using one-way ANOVA followed by Bonferroni’s test.
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DCs, and myeloid cells, from a CD80-deficient 
mouse, showed reduced Arg1 expression and activ-
ity that correlates with accentuated tumor progres-
sion.56 The phenotypic changes in DCs observed in 
the present study arising from the use of iNOS and 
arginase inhibitors suggest that the APC function 
of these cells may be compromised. To test this 
hypothesis, adoptive transfer experiments BMDCs 
modulated with L-NAME and NOHA were con-
ducted in wild-type BALB/c mice and in DO11.10 
transgenic mice.
There are few data in the literature correlating 
alterations in antibody production and the catabo-
lism of L-arginine, most of them coming from a 
transgenic mouse deficient in one of the two 
enzymes. In this regard, it has been shown that the 
NOS2-deficient mouse infected with Influenza A 
virus presents virus titers in the lungs significantly 
lower than those found in the wild-type mouse. This 
enhanced viral clearance seems to correlate with the 
production of higher levels of virus-specific IgG2a 
antibody and  of IFN-gamma by spleen cells from 
Figure 4. Adoptive transfer of BMDCs modulated with L-NAME or NOHA does not affect antibody levels and T-cell proliferation 
but increases cytokine levels in DO11.10 mice. To perform the adoptive transfer, DO11.10 mice (n = 6 per group) were injected 
by intravenous route with 5 × 105 BMDCs cultured in the presence of L-NAME (1 mM) or NOHA (750 μM) for 48 h. A group of 
transgenic mice that received BMDCs cultured in the absence of inhibitors was included as the control. One day later, mice from all 
groups were challenged with 10 mg OVA + 1 mg Al(OH)3 by the intraperitoneal route. At day 14, transgenic mice were boosted 
with 10 mg OVA in saline solution. Seven days after the last antigenic dose, mice were killed for evaluations. Sera were separated for 
measuring anti-OVA antibody levels in indirect ELISA, and spleens and lymph nodes were removed aseptically for measuring antigen 
specific proliferation and cytokine production in supernatants. Cells were cultured in the presence of 100 μg/mL OVA for 96 h. 
Supernatants were collected, complete mediums containing MTT were added to the wells, and plates were incubated for an additional 
4 h. (a) Antibody levels: the bars represent the mean ± SEM of the sum of absorbance values of individual serum dilutions from 1:100 to 
1:12,800 in ELISA assays. (b, c) Cell proliferation: the bars represent the mean of absorbance ± SEM measured in the cultures subtracting 
naïve basal proliferation of spleen (b) and lymph node (c) cells. Cultures were performed in six replicates. (d–l) Cytokine levels: the bars 
represent the mean ± SEM of cytokine concentrations in culture supernatants. Data are representative of two separate experiments. *P 
<0.05 compared with control group. Comparisons were carried out using one-way ANOVA followed by Bonferroni’s test.
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deficient mice.57 On the other hand, Noda et al. 
showed that iNOS-deficient mice were more sus-
ceptible to lethal infection with cytomegalovirus 
than iNOS-expressing mice, and generated a much 
higher peak virus titers in the salivary gland after 
acute infection.58 However, macrophage-Arg1-defi-
cient mice infected with the gastrointestinal hel-
minthes Trichuris muris showed antibody levels 
comparable to wild-type animals in both acute and 
chronic infection.59 In relation to iNOS and arginase 
inhibitors, the literature data have associate treat-
ments with L-NAME to increase in IgG2a isotype 
(from Th1 responses), whereas treatments with 
NOHA have been correlated with increased levels 
of IgG1 (from Th2 responses).14,17–20,40–42
Although there are no specific data relating to 
the effects of inhibition of iNOS and arginase on 
adoptively transfer model of BMDC, literature 
data show conflicting results regarding the effects 
of the absence of iNOS in APCs upon T-cell prolif-
eration. In this regard, Hoffmann et al. showed that 
CD8 T-cell proliferation can be inhibited by lesser 
amounts of APC-derived NO than is necessary to 
inhibit CD4 T-cell proliferation.13 In an attempt to 
identify the underlying molecular mediators of 
immunosuppression, Ren et al. examined how 
apoptotic cells induce immunoregulation by DCs.60 
They found that normal DCs co-cultured with 
apoptotic DCs completely lose their ability to sup-
port T-cell activation. This effect, however, can be 
reversed by inhibitors of iNOS. The authors sug-
gested that the exposure to the apoptotic cells ren-
dered normal DCs capable of producing much 
more NO, such as in a tolerogenic prolife.60
Interestingly, all measured cytokines (IL-2, IFN-
γ, IL-4, IL-10, and TGF-β) were significantly 
increased in MLN cultures obtained from BALB/c 
mice that received BMDCs modulated with NOHA. 
These findings appear to indicate that modulation of 
arginase and iNOS leads to different results depend-
ing on the immune compartment to which the DCs 
migrate. On the other hand, non-modulated BMDCs 
seem to increase the immune response as a whole. A 
possible explanation is that after transfer to immu-
nized mice, non-modulated immature BMDCs 
probably undergo maturation in vivo leading to the 
activation of naïve T cells toward effector popula-
tions Th1 and Th2.3 Although there are some reports 
showing that L-NAME improve Th1 response while 
NOHA reduces this kind of immunity,14,17–20,40–42 
our work differs from those since it shows that the 
transfer of BMDCs modulated with these inhibitors 
reduces both Th1 and Th2 responses in the spleen, 
but increases the two types of responses in lymph 
nodes associated with the intestine.
The activity of both iNOS and Arg1 can also be 
correlated with the capacity of DCs to expand and 
differentiate populations of regulatory T cells in 
the periphery.35,36 In this regard, we observed 
that BMDCs treated with saline or L-NAME 
were able to expand in vitro the population of 
CD4+CD25+Foxp3+ cells in co-cultures with 
TCD4+ cells. Besides, BMDCs modulated with 
L-NAME and NOHA were also able to increase 
the expression of CTLA-4 and CD28 molecules on 
T cells. Since the CTLA-4 molecule has a higher 
affinity to DC receptors (CD80/CD86) than CD28, 
it can be an explanation to the downregulation of 
proliferation and cytokine secretion.6,61
Since adoptive transfer of non-modulated 
BMDCs increases immune response of BALB/c 
mice by augmenting antibody levels, proliferative 
response, and cytokine secretion, a possible expla-
nation is that these cells undergo in vivo matura-
tion leading to the high activation of naïve T cells 
toward both effector populations Th1 and Th2.3
In agreement with our data, it has been shown 
that depletion of L-arginine through arginase in 
cells of myeloid origin is an important mechanism 
of immunosuppression.62,63 The depletion of 
L-arginine in tumor cells affected the activation of 
T cells by inhibiting re-expression of ζ chain CD3 
molecule after the internalization of Ag-TCR com-
plex, which seems to be an efficient mechanism of 
tumor escape.28 Also, “classically activated” or 
“killer” murine macrophages (M1) can be differen-
tiated from “alternatively activated” phenotype or 
“healer” macrophages (M2) by how they metabo-
lize L-arginine. M1 macrophages produce iNOS in 
response to LPS, which uses L-arginine as a sub-
strate to produce NO and higher levels of pro-
inflammatory cytokines. On the other hand, M2 
macrophages constitutively produce the enzyme 
arginase I, which sequesters L-arginine and results 
in the production of ornithine and downstream pol-
yamines and L-proline.64,65 Recent data showed 
that oral supplementation with an inhibitor of argi-
nase named nor-NOHA was able to improve adi-
pose tissue inflammation in obese subjects. The 
authors observed that this treatment altered mac-
rophage phenotype from M1 to M2 in adipose tis-
sue by upregulation of IL-10 messenger RNA.66
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The NOS isoforms have received considerable 
interest since these molecules are potential targets 
of drugs designed for several pathological condi-
tions.67 Inducible NOS-derived NO contributes to 
pathological processes, in particular neurodegen-
erative disorders, inflammation, and pain.67–70 It 
has been shown that iNOS inhibition with L-NAME 
restores antigen-specific T-cell proliferation and 
reduces the percentage of apoptotic cells in cul-
tures of spleen cells in experimental autoimmune 
encephalomyelitis (EAE).71
Increased expression of Arg1 in inflammatory 
infiltrates has been demonstrated in several murine 
models of disease as experimental glomerulone-
phritis, trypanosomiasis, schistosomiasis, leish-
maniosis, viral and bacterial diseases, asthma and 
pulmonary fibrosis, and experimental autoimmune 
encephalomyelitis.72,73 In relation to asthma, it has 
been shown that the administration of nor-NOHA 
significantly reduced the inflammatory process 
induced by treatment with OVA in a model of anti-
gen-induced airway inflammation.74,75
It has been shown that decreased arginine availa-
bility by myeloid-derived suppressor cells led to 
T-cell dysfunction and increased susceptibility to 
infection after physical injury.76 In agreement with 
our data, these effects were reversed by arginase 
inhibitor nor-NOHA, but reproduced by adoptively 
transferring myeloid-derived suppressor cells or 
injecting arginase 1 into control mice.76 Furthermore, 
suppressed CD8+ T-cell proliferation was attenuated 
by the iNOS inhibitor aminoguanidine hydrochlo-
ride and arginase inhibitor N-hydroxy-nor-l-arginine 
(nor-NOHA).77 It has also been shown that MDSC 
play important immunosuppressive role in several 
types of cancers, including head and neck squamous 
cell carcinoma (HNSCC).56 In this regard, Vasquez-
Dunddel et al.78 showed that MDSC collected from 
tumor, draining lymph nodes, and peripheral blood 
from HNSCC patients inhibit autologous antigen-
independent T-cell proliferation. MDSC from all 
three compartments expressed high phosphorylated 
STAT3 levels that correlate with arginase-I expres-
sion levels and activity. The authors also showed that 
Stattic, a STAT3-specific inhibitor, as well as reple-
tion of L-arginine or treatment with nor-NOHA, abol-
ished MDSC’s suppressive function.
Literature showed that T cells obtained from the 
spleens of DO11.10 mice are 80% of CD4+ T cells 
that bore the DO11.10 transgenic TCR (OVA-
specific).79 It has been shown that i.p. injection of 
OVA leads to central and peripheral depletion of 
OVA-specific T CD4+ cells in DO11.10 mice 
(MURPHY; HEIMBERGER; LOH, 1990). 
MacConmara et al.81 confirm that DO-11 mice 
have a significant population of DO-11 TCR-
Tregs, which could influence the OVA323–339 
peptide immune response when co transferred into 
Treg-depleted mice.81 Data obtained in our lab, 
however, shows that even in the presence of exten-
sive reduction of mature anti-OVA T cells, 
DO11.10 mice are able to produce a significant 
humoral immune response following immuniza-
tion with OVA.5 Since anti-OVA specific T cells 
represent the major population of TCD4+ cells in 
peripheral blood of DO11.10 mice,80 transfer of 
modulated BMDCs would not be enough to mod-
ify the immune response in these transgenic mice. 
In fact, as we previously report, DO11.10 mice 
were not susceptible to the induction of oral toler-
ance or adoptive transfer of DCs from tolerant 
mice, as measured by its antibody levels, prolifer-
ation of T cells, and levels of CD86 molecules.5 
Data obtained here show that adoptive transferring 
of iNOS- or arginase-blocked BMDCs to the 
transgenic mice had the ability of modify the 
cytokine production in spleen and MLN cell cul-
tures, but had few reflex in its in vivo immune 
response. The literature shows that T cells obtained 
from the spleens of DO11.10 mice are 80% of 
CD4+ T cells that bore the OVA transgenic TCR 
(OVA-specific).8,9,82 As we already described, 
DO11.10 mice are highly responsive to OVA, 
including orally.5,10,83 So, we can presume that dis-
crepancies among BALB/c and DO11.10 response 
can be due to the elevated number of OVA-specific 
TCR found in DO11.10 mice.
Hultkrantz and collaborators84 adoptively trans-
ferred cells from DO11.10 transgenic mice and 
evaluated the response in different lymphoid 
organs. Antigen-specific CD4+ T cells were acti-
vated in the liver-draining celiac lymph node 
(CLN) after ovalbumin feeding. The significantly 
higher proportion of the T cells in the CLN devel-
oped into the putative regulatory phenotype than in 
Peyer’s patches, the mesenteric and peripheral 
lymph nodes, and the spleen. The expression of 
FoxP3 was not upregulated in any of the lymph 
node compartments. The phenotypic and func-
tional findings suggest that the induction of regula-
tory T cells in the CLN may be relevant in the 
control of the immune response to dietary antigens. 
Also, Zinselmeyer et al.85 tracked antigen-specific 
CD4+ T lymphocytes in real time, in situ during the 
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induction of oral priming versus oral tolerance. 
They observed a marked contrast with respect to 
rate and type of movement and clustering between 
naïve T cells and those exposed to immunogenic or 
tolerogenic antigen. Egan et al.86 adoptively trans-
ferred CD4+, KJ1-26+ T lymphocytes from trans-
genic mice to BALB/c mice. These authors 
suggested that repeated and systemic exposure of T 
cells to their cognate Ag in the absence of “danger” 
signals induces initial T-cell priming and clonal 
expansion, but results in an anergic phenotype, 
corroborating our data.
Also, our data showed that iNOS and Arg modu-
lation inhibit the function of in vitro generated 
DCs. The treatment with iNOS and Arg inhibitors 
leads to augmented expression of co-stimulatory 
molecules that are important for antigen presenta-
tion by DCs. Adoptive transfer of BMDCs treated 
with L-NAME or NOHA was able to modulate the 
immune response in immunized BALB/c mice, 
mimicking the functions of tolerogenic DCs. 
However, none of the treatments with BMDCs was 
able to modulate the immune response of DO11.10 
transgenic mice.
The present study indicates that modulation of 
BMDCs with pharmacological inhibitors of NOS 
and Arg provides a mechanism of inhibition of 
antigen-specific responses, possibly by increasing 
co-stimulatory molecules on effector T cells and 
stimulating Treg cells in BALB/c mice. Although 
the modulatory mechanism may be related to co-
stimulatory molecules and Treg cells, further stud-
ies on the mechanisms of action are still necessary. 
This study provides evidence that L-arginine 
metabolism in DCs may be an important therapeu-
tic target for controlling immune responses in 
inflammatory disorders.
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